The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure

Ovidio De Freitas, Oliver Lenz, Alessia Fornoni, Barry J Materson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

About 5 million Americans suffer from heart failure. Given the correlation of heart failure with age and the rising life expectancy, the prevalence of heart failure continues to increase in the general population. Sympathetic stimulation intensifies with progressive heart failure. The rationale to use β-blockers in individuals with impaired myocardial function is based on experimental evidence supporting the notion that prolonged α- and β-adrenergic stimulation leads to worsening heart failure. Until recently, safety concerns have precluded the use of β-blockers in patients with diabetes and heart failure. However, several large, randomized, placebo-controlled clinical trials such as Metoprolol Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) have shown that β-blockers can be safely used in patients with diabetes and heart failure. Moreover, β-blockers significantly improved morbidity and mortality in this population. Based on this evidence, it is now recommended to add β-blockers such as metoprolol CR/XL with an escalating dosage regimen to the treatment of patients with symptomatic heart failure who already are receiving a stable medical regimen including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, diuretics, vasodilators, or digitalis.

Original languageEnglish
Pages (from-to)139-144
Number of pages6
JournalVascular Health and Risk Management
Volume2
Issue number2
DOIs
StatePublished - Jun 15 2006

Fingerprint

Metoprolol
Heart Failure
Therapeutics
Digitalis
Angiotensin Receptor Antagonists
Life Expectancy
Vasodilator Agents
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Adrenergic Agents
Population
Randomized Controlled Trials
Placebos
Morbidity
Safety
Mortality

Keywords

  • Β-adrenergic blocking agents
  • Diabetes mellitus
  • Heart failure
  • MERIT-HF
  • Metoprolol

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health
  • Hematology
  • Endocrinology, Diabetes and Metabolism

Cite this

The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure. / De Freitas, Ovidio; Lenz, Oliver; Fornoni, Alessia; Materson, Barry J.

In: Vascular Health and Risk Management, Vol. 2, No. 2, 15.06.2006, p. 139-144.

Research output: Contribution to journalArticle

@article{399518418cd84f25a9f38074e9f5612a,
title = "The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure",
abstract = "About 5 million Americans suffer from heart failure. Given the correlation of heart failure with age and the rising life expectancy, the prevalence of heart failure continues to increase in the general population. Sympathetic stimulation intensifies with progressive heart failure. The rationale to use β-blockers in individuals with impaired myocardial function is based on experimental evidence supporting the notion that prolonged α- and β-adrenergic stimulation leads to worsening heart failure. Until recently, safety concerns have precluded the use of β-blockers in patients with diabetes and heart failure. However, several large, randomized, placebo-controlled clinical trials such as Metoprolol Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) have shown that β-blockers can be safely used in patients with diabetes and heart failure. Moreover, β-blockers significantly improved morbidity and mortality in this population. Based on this evidence, it is now recommended to add β-blockers such as metoprolol CR/XL with an escalating dosage regimen to the treatment of patients with symptomatic heart failure who already are receiving a stable medical regimen including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, diuretics, vasodilators, or digitalis.",
keywords = "Β-adrenergic blocking agents, Diabetes mellitus, Heart failure, MERIT-HF, Metoprolol",
author = "{De Freitas}, Ovidio and Oliver Lenz and Alessia Fornoni and Materson, {Barry J}",
year = "2006",
month = "6",
day = "15",
doi = "10.2147/vhrm.2006.2.2.139",
language = "English",
volume = "2",
pages = "139--144",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",
number = "2",

}

TY - JOUR

T1 - The use of metoprolol CR/XL in the treatment of patients with diabetes and chronic heart failure

AU - De Freitas, Ovidio

AU - Lenz, Oliver

AU - Fornoni, Alessia

AU - Materson, Barry J

PY - 2006/6/15

Y1 - 2006/6/15

N2 - About 5 million Americans suffer from heart failure. Given the correlation of heart failure with age and the rising life expectancy, the prevalence of heart failure continues to increase in the general population. Sympathetic stimulation intensifies with progressive heart failure. The rationale to use β-blockers in individuals with impaired myocardial function is based on experimental evidence supporting the notion that prolonged α- and β-adrenergic stimulation leads to worsening heart failure. Until recently, safety concerns have precluded the use of β-blockers in patients with diabetes and heart failure. However, several large, randomized, placebo-controlled clinical trials such as Metoprolol Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) have shown that β-blockers can be safely used in patients with diabetes and heart failure. Moreover, β-blockers significantly improved morbidity and mortality in this population. Based on this evidence, it is now recommended to add β-blockers such as metoprolol CR/XL with an escalating dosage regimen to the treatment of patients with symptomatic heart failure who already are receiving a stable medical regimen including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, diuretics, vasodilators, or digitalis.

AB - About 5 million Americans suffer from heart failure. Given the correlation of heart failure with age and the rising life expectancy, the prevalence of heart failure continues to increase in the general population. Sympathetic stimulation intensifies with progressive heart failure. The rationale to use β-blockers in individuals with impaired myocardial function is based on experimental evidence supporting the notion that prolonged α- and β-adrenergic stimulation leads to worsening heart failure. Until recently, safety concerns have precluded the use of β-blockers in patients with diabetes and heart failure. However, several large, randomized, placebo-controlled clinical trials such as Metoprolol Randomized Intervention Trial in Congestive Heart Failure (MERIT-HF) have shown that β-blockers can be safely used in patients with diabetes and heart failure. Moreover, β-blockers significantly improved morbidity and mortality in this population. Based on this evidence, it is now recommended to add β-blockers such as metoprolol CR/XL with an escalating dosage regimen to the treatment of patients with symptomatic heart failure who already are receiving a stable medical regimen including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, diuretics, vasodilators, or digitalis.

KW - Β-adrenergic blocking agents

KW - Diabetes mellitus

KW - Heart failure

KW - MERIT-HF

KW - Metoprolol

UR - http://www.scopus.com/inward/record.url?scp=33744956774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744956774&partnerID=8YFLogxK

U2 - 10.2147/vhrm.2006.2.2.139

DO - 10.2147/vhrm.2006.2.2.139

M3 - Article

C2 - 17319457

AN - SCOPUS:33744956774

VL - 2

SP - 139

EP - 144

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

IS - 2

ER -